Skip to main content
. 2019 Feb 5;3(1):15–29. doi: 10.3233/KCA-180043

Table 1.

Ongoing Clinical Trials of Glutaminase Inhibitor CB-839 in Solid Tumors

clinicaltrials.gov Identifier Title Phase
NCT02071862 Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Phase I (ref. [153])
NCT02771626 Study of CB-839 in Combination With Nivolumab in Patients With Melanoma, ccRCC and NSCLC Phase I/II
NCT03163667 Study of CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC (ENTRATA Trial) Randomized Phase II
NCT03428217 Study of CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic RCC (CANTATA Trial) Randomized Phase II